NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.02 +0.02 (+0.03%) GOLD FUTURES
2,315.60 +4.60 (+0.20%) DOW
38,234.31 +331.02 (+0.87%) Bitcoin GBP
47,266.89 +465.04 (+0.99%)
Rakovina Therapeutics Inc. (RKV.V)
| Previous close | 0.0850 |
| Open | 0.0850 |
| Bid | 0.0850 x N/A |
| Ask | 0.0900 x N/A |
| Day's range | 0.0850 - 0.0850 |
| 52-week range | 0.0050 - 0.1600 |
| Volume | |
| Avg. volume | 75,339 |
| Market cap | 5.936M |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings date | 29 May 2024 - 03 Jun 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireRakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update
VANCOUVER, British Columbia, April 26, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and provided a corporate update. 2023 Highlights and Recent Developments On March 27, 2024 we announced a collaboration agreement with Dr. Artem Cherkasov granting R
- GlobeNewswire
Rakovina Therapeutics Presented at American Association of Cancer Research Annual Meeting at the San Diego Convention Center Today
VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of novel DNA-damage response inhibitor therapeutics, is pleased to announce that members of the Company’s scientific team presented new data on the Company’s novel kt-3000 series at the American Association of Cancer Research (AACR) Annual Meeting at the San D
- GlobeNewswire
Rakovina Therapeutics To Host Informational Webinar on April 3, 2024
Announces Capital Markets Advisory AgreementVANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina Therapeutics” or the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of novel DNA-damage response inhibitor therapeutics, will be hosting an informational webinar on Wednesday, April 3, 2024. The Rakovina leadership team and members of the scientific team will host the co
